Literature DB >> 16530325

Breast cancer markers.

Vincenzo Giancotti1.   

Abstract

This review illustrates the relationships linking the ER and the ErbB family of receptor tyrosine kinases and their kinase pathways in breast cancer. The central role of the ER in activating tumour growth linked gene transcription as well as the cooperating nuclear co-factors very likely implicated in breast cancer tumourigenesis is discussed. The action of ErbB family members has been located upstream of the kinase pathways that begin at plasma membrane and end at the nucleus after complex interconnections with many factors, such as AP-1. The important role of MAPKs and PKB/Akt in cell survival and tumour proliferation is highlighted. Also other factors are discussed such as Fra-1 (a member of the AP-1 complex), E-cadherin (a tumour suppressor), and BRCA1 (another factor involved in tumour growth inhibition). Lactoferrin protein (characteristic of healthy tissues) and resistance proteins have also been briefly discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16530325     DOI: 10.1016/j.canlet.2006.01.035

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  15 in total

1.  Induction of apoptosis by Trichostatin A in human breast cancer cell lines: involvement of 15-Lox-1.

Authors:  Masoumeh Tavakoli-Yaraki; Fatemeh Karami-Tehrani; Vahid Salimi; Majid Sirati-Sabet
Journal:  Tumour Biol       Date:  2012-10-06

2.  Involvement of 15-lipoxygenase-1 in the regulation of breast cancer cell death induced by sodium butyrate.

Authors:  Vahid Salimi; Mohammad Shabani; Mitra Nourbakhsh; Masoumeh Tavakoli-Yaraki
Journal:  Cytotechnology       Date:  2016-05-12       Impact factor: 2.058

Review 3.  Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance.

Authors:  Kimmo J Hatanpaa; Sandeep Burma; Dawen Zhao; Amyn A Habib
Journal:  Neoplasia       Date:  2010-09       Impact factor: 5.715

4.  The effects of p38 gene silencing on breast cancer cells.

Authors:  Fulya Doğaner; Didem Turgut Coşan; Hasan Veysi Güneş; Irfan Değirmenci; Cengiz Bal
Journal:  Mol Biol Rep       Date:  2014-01-28       Impact factor: 2.316

5.  ERK signaling regulates tumor promoter induced c-Jun recruitment at the Fra-1 promoter.

Authors:  Pavan Adiseshaiah; Jinfang Li; Michelle Vaz; Dhananjaya V Kalvakolanu; Sekhar P Reddy
Journal:  Biochem Biophys Res Commun       Date:  2008-04-22       Impact factor: 3.575

6.  Dual-wavelength imaging of tumor progression by activatable and targeting near-infrared fluorescent probes in a bioluminescent breast cancer model.

Authors:  Bang-Wen Xie; Isabel M Mol; Stijn Keereweer; Ermond R van Beek; Ivo Que; Thomas J A Snoeks; Alan Chan; Eric L Kaijzel; Clemens W G M Löwik
Journal:  PLoS One       Date:  2012-02-13       Impact factor: 3.240

7.  Potential therapeutic mechanism of genistein in breast cancer involves inhibition of cell cycle regulation.

Authors:  Ling Zhang; Bo Yang; Ke Zhou; Hua Li; Dong Li; Hui Gao; Tao Zhang; Dong Wei; Zhihui Li; Yong Diao
Journal:  Mol Med Rep       Date:  2014-11-10       Impact factor: 2.952

8.  Id2 promotes the invasive growth of MCF-7 and SKOV-3 cells by a novel mechanism independent of dimerization to basic helix-loop-helix factors.

Authors:  Yuanguang Meng; Chenglei Gu; Zhiqiang Wu; Yali Zhao; Yiling Si; Xiaobing Fu; Weidong Han
Journal:  BMC Cancer       Date:  2009-03-04       Impact factor: 4.430

9.  An improved model to study tumor cell autonomous metastasis programs using MTLn3 cells and the Rag2(-/-) gammac (-/-) mouse.

Authors:  Sylvia E Le Dévédec; Wies van Roosmalen; Naomi Maria; Max Grimbergen; Chantal Pont; Reshma Lalai; Bob van de Water
Journal:  Clin Exp Metastasis       Date:  2009-05-24       Impact factor: 5.150

10.  Genome-wide pathway analysis reveals different signaling pathways between secreted lactoferrin and intracellular delta-lactoferrin.

Authors:  Byungtak Kim; Seongeun Kang; Sun Jung Kim
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.